MedTrace Logo

Comparison of Dendritic Cell-Based Therapeutic Vaccine Strategies for HIV Functional Cure

NCT03758625 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2025-10-29

No results posted yet for this study

Summary

This study will be done in people living with HIV to see if an investigational vaccine made from a person's own white blood cells is safe and tolerated. This study will also look at the body's immune response to the vaccine and evaluate four different methods of making the vaccine to see which method may result in better immune responses.

Conditions

  • HIV Infections

Interventions

BIOLOGICAL

a1DC + inactivated whole autologous HIV

Investigational vaccine composed of autologous dendritic cells matured with an optimized cocktail (a1DC) and loaded with autologous -inactivated HIV

BIOLOGICAL

a1DC + conserved HIV peptides

Investigational vaccine composed of autologous dendritic cells matured with an optimized cocktail (a1DC) and loaded with a conserved HIV gag and pol peptide pool

BIOLOGICAL

a1DC + no antigen

Control vaccine composed of autologous dendritic cells matured with an optimized cocktail (a1DC) but without an antigen

BIOLOGICAL

pgDC + inactivated whole autologous HIV

Investigational vaccine composed of autologous dendritic cells matured with a standard prostaglandin E2 cocktail (pgDC) and loaded with autologous -inactivated HIV

BIOLOGICAL

pgDC + conserved HIV peptides

Investigational vaccine composed of autologous dendritic cells matured with a standard prostaglandin E2 cocktail (pgDC) and loaded with a conserved HIV gag and pol peptide pool

BIOLOGICAL

pgDC + no antigen

Control vaccine composed of autologous dendritic cells matured with a standard prostaglandin E2 cocktail (pgDC) but without an antigen

Sponsors & Collaborators

  • National Institute of Allergy and Infectious Diseases (NIAID)

    collaborator NIH

  • Sharon Riddler

    lead OTHER

Principal Investigators

  • Sharon Riddler, MD · University of Pittsburgh

  • Bernard Macatangay, MD · University of Pittsburgh

  • John Mellors, MD · University of Pittsburgh

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-02
Primary Completion
2025-02-19
Completion
2025-02-19
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03758625 on ClinicalTrials.gov